Koray ACARLI, Serdar TOPALOĞLU, İlhan OCAK

Posthepatectomy liver failure

Liver surgery is one of the most complex surgical interventions with high risk and potential for complications. Posthepatectomy liver failure (PHLF) is a serious complication of liver surgery that occurs in about 10% of patients undergoing major liver surgery. It is the main source of morbidity and mortality. Appropriate surgical techniques and intensive care management are important in preventing PHLF. Early start of the liver support systems is very important for the PHLF patient to recover, survive, or be ready for a liver transplant. Nonbiological and biological liver support systems should be used in PHLF to prepare for treatm

PDF

___

1. RahbariNN, Garden OJ, Padbury R, Maddern G, Koch Met al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery 2011; 149: 713-724. doi: 10.1111/j.1477-2574.2011.00319.x
2. Paugam-Burtz C, Janny S, Delefosse D, Dahmani S, Dondero F et al. Prospective validation of the ‘fifty-fifty’ criteria as an early and accurate predictor of death after liver resection in intensive care unit patients. Annals of Surgery 2009; 249: 124-128. doi: 10.1097/SLA.0b013e31819279cd.
3. Hammond JS, Guha IN, Beckingam IJ, Lobo DN. Prediction, prevention, and management of postresection liver failure. British Journal of Surgery 2011; 98: 1188-1200. doi: 10.1002/ bjs.7630
4. Mullen JT, Ribero D, Reddy SK, Donadon M, Zorzi Det al. Hepatic insufficiency and mortality in 1059 noncirrhotic patients undergoing major hepatectomy. Journal of the American College of Surgeons 2007; 204: 854-862. doi: 10.1016/j.jamcollsurg.2006.12.032
5. Michalopoulos GK. Liver regeneration. Journal of Cellular Physiology 2007; 213: 286-300. doi: 10.1002/jcp.21172
6. Fausto N. Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. Hepatology 2004; 39: 1477- 1487. doi: 10.1002/hep.20214
7. Clavien PA, Oberkofler CE, Raptis DA, Lehmann K,Rickenbacher A, El-Badry AM. What is critical for liver surgery and partial liver transplantation: size or quality? Hepatology 2010; 52: 715-729. doi: 10.1002/hep.23713
8. Demetris AJ, Kelly DM, Eghtesad B, Fontes P, Marsh JW et al. Pathophysiologic observations and histopathologic recognition of the portal hyperperfusion or small-for-size syndrome. American Journal of Surgical Pathology 2006; 30: 986-993. doi: 10.1097/00000478-200608000-00009
9. Cornell R. Gut-derived endotoxin elicits hepatotrophic factor secretion of liver regeneration. American Journal of Physiology 1985; 249: R551-R562. doi: 10.1152/ ajpregu.1985.249.5.R551
10. Boermeester MA, Straatsburg IH, Houdijk AP, Meyer C, Frederiks WM et al. Endotoxin and interleukin-1 related hepatic inflammatory response promotes liver failure after partial hepatectomy. Hepatology 1995; 22: 1499-1506. doi: 10.1002/hep.1840220525
11. Panis Y, McMullan DM, Emond JC. Progressive necrosis after hepatectomy and the pathophysiology of liver failure after massive resection. Surgery 1997; 121: 142-149. doi: 10.1016/s0039-6060(97)90283-x
12. Jaeschke H. Molecular mechanisms of hepatic ischemia– reperfusion injury and preconditioning. American Journal of Physiology Gastrointestinal and Liver Physiology 2003; 284: G15–G26. doi: 10.1152/ajpgi.00342.2002
13. Selzner N, Rudiger H, Graf R, Clavien P-A. Protective strategies against ischemic injury of the liver. Gastroenterology 2003; 125: 917-936. doi: 10.1016/s0016- 5085(03)01048-5
14. Pereyra D, Offensperger F, Klinglmueller F, Haegele S, Oehlberger L et al. Early prediction of postoperative liver dysfunction and clinical outcome using antithrombin IIIactivity. Plos One 2017. doi: 10.1371/journal.pone.0175359
15. Oguz S, Tayar S, Topaloglu S, Calik A, Dinc H, Ozturk MH. Enhancing hepatic microcirculation in postoperative hepatic failure with intra-arterial recombinant tissue plasminogen activator treatment. Experimental and Clinical Transplantation 2017; doi: 10.6002/ect.2017.0074
16. Oğuz Ş, Yıldırım R, Topaloğlu S. Role of percutaneous transhepatic biliary drainage in the management of blunt liver trauma: A case report. Ulusal Travma ve Acil Cerrahi Dergisi 2017; 23: 441-444. doi: 10.5505/tjtes.2017.52196
17. Lei J, Ji X, Hong J, Li WB, Chen Yet al. Prediction of post hepatectomy liver failure using transient elastography in patients with hepatitis B related hepatocellular carcinoma. British Medical Council Gastroenterology 2017; 17: 171. doi: 10.1186/s12876-017-0732-4
18. Nishio T, Taura K, Koyama Y, Tanabe K, Yamamoto G et al. Prediction of post hepatectomy liver failure based on liver stiffness measurement in patients with hepatocellular carcinoma. Surgery 2016; 159: 399-408. doi: 10.1016/j. surg.2015.06.024
19. Chen X, Zou H, Xiong L, Huang SF, Miao XY, Wen Y. Predictive power of splenic thickness for post-hepatectomy liver failure in HBV associated hepatocellular carcinoma patients. World Journal of Surgical Oncology 2017; 15: 216. doi: 10.1186/ s12957-017-1281-6
20. O’Grady JG. Management of liver failure. Surgery of the Liver, Biliary Tract, and Pancreas. (Eds: Blumgart LH) Saunders, 2007. pp. 1541-1547.
21. Watanabe FD, Rosenthal P. Medical therapy. In: Demetriou AA (editor): Support of the Acutely Failing Liver. Austin, RG Landes, 1996. pp. 22-32.
22. Harry R, Auzinger G, Wendon J. The clinical importance of adrenal insufficiency in acute hepatic dysfunction. Hepatology 2002; 36: 395-402. doi: 10.1053/jhep.2002.34514
23. Murphy N, Auzinger G, Bernel W, Wendon J. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology 2004; 39: 464-470. doi: 10.1002/hep.20056
24. Jalan R, Sen S, Williams R. Prospects for extracorporeal liver support. Gut 2004; 53: 890-898. doi: 10.1136/gut.2003.024919
25. Fong Y, Moldawer LL, Shires GT, Lowry SF. The biologic characteristics of cytokines and implication in surgical injury. Surgical Gynecolology Obstetrics 1990; 170: 363-378.
26. Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamura M. Continuous hemofiltration/hemodiafiltration in critical care. Therapeutic Apheresis 2002; 6: 193-198. doi: 10.1046/j.1526-0968.2002.00431.x.
27. Carcillo JA. Multiple organ system extracorporeal support in critically ill children. Pediatric Clinics of North America 2008; 55: 617-646. doi: 10.1016/j.pcl.2008.03.002
28. Goldstein SL, Somers MJ, Baum MA, Symons JM, Brophy PDet al. Pediatric patients with multiple organ dysfunction syndrome receiving continuous renal replacement therapy. Kidney Internattional 2005; 67: 653-658. doi: 10.1111/j.1523- 1755.2005.67121.x
29. Ronco C, Bellomo R, Ricci Z. Continuous renal replacement therapy in critically ill patients. Nephrology Dialysis Transplantation 2001; 16(suppl): 67-72. doi: 10.1093/ndt/16. suppl_5.67
30. Ronco C. Recent evolution of renal replacement therapy in the critically ill patient. Critical Care 2006; 10: 123-128. doi: 10.1186/cc4843
31. Clemmesen JO, Kondrup J, Nielsen LB, Larsen FS, Ottet P. Effects of high-volume plasmapheresis on ammonia, urea, and amino acids in patients with acute liver failure. American Journal of Gastroenterology 2001; 96: 1217- 1223. doi: 10.1111/j.1572-0241.2001.03706.x
32. Baumbauer R, el-Saadi R, Graf N, Jesberger HJ, Limbach HG, Cordes H. Plasmapheresis in newborns with hyperbilirubinemia. Artificial Organs 1992; 16: 472-476. doi: 10.1111/j.1525-1594.1992.tb00326.x
33. Kondrup J, Almdal T, Vilstrup H, Tygstrup N. High volume plasma exchange in fulminant hepatic failure. International Journal of Artificial Organs 1992; 15: 669-676.
34. Nakae H, Asanuma Y, Tajimi K. Cytokine removal by plasma Exchange with continuous hemodiafiltration in critically ill patients. Therapeutic Apheresis 2002; 6: 419- 424. doi: 10.1046/j.1526-0968.2002.00464.x
35. Akdogan M, Camci C, Gurakar A, Gilcher R, Alamian Set al. The effect of total plasma Exchange on fulminant hepatic failure. Journal of Clinical Apheresis 2006; 21: 96-99. doi: 10.1002/jca.20064
36. Ozdemir FN, Tutal E, Sezer S, Gür G, Bilgic A, Haberal M. Effect of supportive extracorporeal treatment in liver transplantation recipients and advanced liver failure patients. Hemodialysis International 2006; 10: S28-S32. doi: 10.1111/j.1542-4758.2006.00113.x
37. Inoue K, Kourin A, Watanabe T, Yamada M, Yoshiba M. Artificial liver support system using large buffer volumes removes significant glutamine and is an ideal bridge to liver transplantation. Transplantation Proceedings 2009; 41: 259-261. doi: 10.1016/j.transproceed.2008.10.058
38. van de Kerkhove MP, Hoekstra R, Chamuleau RA, van Gulik TM. Clinical application of bioartificial liver support systems. Annals of Surgery 2004; 240: 216-230. doi: 10.1097/01.sla.0000132986.75257.19
39. O’Grady JG, Gimson AE, O’Brien CJ,Pucknell A, Hughes RD, Williams R. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988; 94: 1186-1192. doi: 10.1016/0016-5085(88)90011-x
40. Stadlbauer V, Krisper P, Aigner R, Haditsch B, Jung Aet al. Effect of extracorporeal liver support by MARS and PROMETHEUS on serum cytokines in acute-on-chronic liver failure. Critical Care 2006; 10: R169. doi: 10.1186/ cc5119
41. Sen S, Davies NA, Mookerkee RP, Cheshire LM, Hodges SJ et al. Pathophysiological effects of albumin dialysis in acute on chronic liver failure: a randomized controlled study. Liver Transplantation 2004; 10: 1109-1119. doi: 10.1002/ lt.20236
42. Laleman W, Wilmer A, Evenepoel P, Elst IV, Zeegers M et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Critical Care 2006; 10: R108. doi: 10.1186/cc4985
43. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transplantation 2000; 6: 277-286. doi: 10.1002/lt.500060326
44. Topaloglu S, Yankol Y, Kücükkartallar T, Ocak İ, Doğruer K et al. Karaciğeryetmezliğitedavisinde nonbiyolojikdesteksistemlerininyeri. YoğunBakımDergisi 2010; 1: 14-20.
45. Sorrentino F. Prime ricerche per la realizzazione di unfegatoartificiale. ChirPatolSperim 1956; 4: 1401-1404 (in Italian).
46. Abouna GM, Ganguly PK, Hamdy HM, Jabur SS, Tweed WA, Costa G. Extracorporeal liver perfusion system for successful hepatic support pending liver regeneration or liver transplantation: a pre-clinical controlled trial. Transplantation 1999; 67: 1576-1583. doi: 10.1097/00007890-199906270-00012
47. Horslen SP, Hammel JM, Fristoe LW, Kangas JA, Collier DS et al. Extracorporeal liver perfusion using human and pig livers for acute liver failure. Transplantation 2000; 70: 1472- 1478. doi: 10.1097/00007890-200011270-00014 48. Strom S, Fisher R. Hepatocyte transplantation: new possibilities for therapy. Gastroenterology 2003; 124: 568- 571. doi: 10.1053/gast.2003.50072
49. Matsumura KN, Guevara GR, Huston H, Hamilton WL, Rikimaru Met al. Hybrid bioartificial liver in hepatic failure: preliminary clinical report. Surgery 1987; 101: 99-103.
50. Margulis MS, Erukhimov EA, Andreiman LA, Viksna LM. Temporary organ substitution by hemoperfusion through suspension of active donor hepatocytes in a total complex of intensive therapy in patients with acute hepatic insufficiency. Resuscitation 1989; 18: 85-94. doi: 10.1016/0300-9572(89)90115-9
51. Gislason GT, Lobdell DD, Kelly JH, Sussman NL. A treatment system for implementing an extracorporeal liver assist device. Artificial Organs 1994; 18: 385-389. doi: 10.1111/j.1525-1594.1994.tb02220.x
52. Demetriou AA, Rozga J, Podesta L, Lepage E, Morsiani Eet al. Early clinical experience with a hybrid bioartificial liver. Scandinavian Journal of Gastroenterology Supplements 1995; 208: 111-117. doi: 10.3109/00365529509107771
53. Xue YL, Zhao SF, Luo Y, Li XJ, Duan ZPet al. TECA hybrid artificial liver support system in treatment of acute liver failure. World Journal of Gastroenterology 2001; 7: 826-829. doi: 10.3748/wjg.v7.i6.826
54. Mazariegos GV, Kramer DJ, Lopez RC, Shakil AO, RosenbloomAJ et al. Safety observations in phase I clinical evaluation of the Excorp Medical Bioartificial Liver Support System after the first four patients. American Society of Artificial Internal Organs Journal 2001; 47: 471-475. doi: 10.1097/00002480-200109000-00015
55. Morsiani E, Pazzi P, Puviani AC, Brogli M, Valieri L et al. Early experiences with a porcine hepatocyte-based bioartificial liver in acute hepatic failure patients. International Journal of Artificial Organs 2002; 25: 192-202. doi: 10.1177/039139880202500305
56. van de Kerkhove MP, Di Florio E, Scuderi V, Mancini A, Belli A et al. Phase I clinical trial with the AMC-bioartificial liver. Academic Medical Center. International Journal of Artificial Organs 2002; 25: 950-959. doi: 10.1177/039139880202501009